A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

NCT01635621 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Study was withdrawn due to delay in timelines. There were no safety concerns regarding the study or the compound in the decision to withdraw the trial.

Conditions

Interventions

Sponsor

UCB BIOSCIENCES GmbH